MA
Mohamed Abdel-Moneim

Established

12
Works
46
Citations
4
H-Index
Search Authors
Author Statistics
  • OpenAlex ID A5090667364
  • i10-Index 2
  • 2-Yr Mean Citedness 0.00
External Links
OpenAlex Profile

Mohamed Abdel-Moneim

Also known as: Mohamed Abdel-Moneim

12

Total Works

46

Citations

4

H-Index

2

i10-Index

Citation & Works Trend by Year
7 years active
Top Research Topics
Blood Pressure and Hypertension Studies (6) Cardiovascular Health and Disease Prevention (5) Sodium Intake and Health (4) Venous Thromboembolism Diagnosis and Management (3) Blood Coagulation and Thrombosis Mechanisms (3)
Recent Publications
12 shown
Year Publication Title Citations Action
2026 Publisher Correction: Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis Obesity Surgery 0
2026 Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis Obesity Surgery 0
2026 Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis Research and Practice in Thrombosis and Haemostasis 0
2025 Long-term event rates, risk factors, and treatment pattern in 1.4 million individuals qualifying for dual blood pressure lowering therapy Journal of Hypertension 3
2024 Effect of single-pill versus free equivalent combinations on persistence and major adverse cardiovascular events in hypertension: a real-world analysis Journal of Hypertension 13
2024 Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals European Heart Journal - Cardiovascular Pharmacotherapy 8
2023 IMPACT OF RAMIPRIL/AMLODIPINE DOSE COMBINATIONS OF SINGLE-PILL VERSUS FREE EQUIVALENT COMBINATIONS ON PERSISTENCE AND MAJOR ADVERSE CARDIOVASCULAR EVENTS: A REAL-WORLD ANALYSIS Journal of Hypertension 1
2023 LONG-TERM EVENT RATES, RISK FACTORS, AND TREATMENT PATTERN IN PATIENTS QUALIFYING FOR DUAL BLOOD PRESSURE-LOWERING THERAPY: AN OBSERVATIONAL STUDY IN 1.4 MILLION INDIVIDUALS Journal of Hypertension 1
2023 A Bioequivalence Study of Ezetimibe/Rosuvastatin Fixed Dose Combination (10 mg/10 mg) Versus the Individual Formulations Taken Concomitantly Advances in Therapy 4
2023 Event Rates, Risk-Factors, and Blood Pressure-Lowering Treatment Patterns in Patients Qualifying for Dual Blood Pressure-Lowering Therapy: An Observational Study in 1.4 Million Individuals with a 15-Year Follow-Up SSRN Electronic Journal 0
2022 Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants European Journal of Drug Metabolism and Pharmacokinetics 10
2016 Can Serum Levels of C-Reactive Protein (CRP), Interleukin-6 and Copeptin Discriminate between Simple and Complex Febrile Seizures? International Neuropsychiatric Disease Journal 6

Data source: OpenAlex API